#USA #Braintree #Sebela Pharmaceuticals #Tegoprazan #NERD

Positive Developments in NERD Treatment

Recently, Sebela Pharmaceuticals shared noteworthy findings from their Phase 3 TRIUMpH clinical trial program regarding the investigational drug Tegoprazan, aimed at treating non-erosive reflux disease (NERD). This update came during the American College of Gastroenterology (ACG) 2026 Meeting, signaling a potential breakthrough for patients suffering from this common gastrointestinal disorder.

What is NERD?

NERD represents a significant form of gastroesophageal reflux disease (GERD), where patients experience reflux symptoms—such as heartburn and regurgitation—without visible erosive damage to the esophagus. Despite existing treatment options, many individuals continue to face persistent symptoms, indicating an unmet need for more effective solutions.

Study Highlights

The TRIUMpH-NERD study is a multicenter, randomized, double-blind, placebo-controlled trial that enrolled 783 patients experiencing symptomatic NERD. Participants were administered either Tegoprazan at 50mg or 100mg doses, or a placebo, over a four-week period, followed by a 20-week extension phase. Key findings from the study revealed:

• - Tegoprazan resulted in significant improvements in the percentage of 24-hour heartburn-free days when compared to placebo.
• - Both dosages of the drug improved the percentage of days patients were free from nighttime heartburn, further enhancing the quality of life for participants.
• - Patients on Tegoprazan reported more days without regurgitation and fewer combined symptoms of heartburn and regurgitation.

Data analyses indicated that treatment effects began on Day 1 of administration and continued to improve over the extension period. The success of this trial not only bolsters the drug’s efficacy against NERD but also addresses crucial treatment gaps for individuals afflicted by GERD.

Alan Cooke's Perspective

Alan Cooke, the President and CEO of Sebela Pharmaceuticals, remarked, "The findings from the NERD and erosive esophagitis analyses enhance our understanding of Tegoprazan across major GERD phenotypes, showcasing the sustained improvement we can offer to patients experiencing these challenging symptoms." This statement highlights Sebela’s commitment to advancing medical solutions for populations with GERD, underlining how the trial's findings can potentially shift treatment paradigms.

ACG Recognition

In addition to the NERD data, a separate analysis focusing on erosive esophagitis that was also part of the TRIUMpH study gained recognition at ACG through a presidential award. This praised analysis illustrated that patients with erosive esophagitis demonstrated superior healing effects while using Tegoprazan as compared to traditional treatments like lansoprazole. These outcomes affirm the potential of Tegoprazan not only for NERD but also for patients suffering from more severe GERD manifestations.

Future Endeavors

With the data revealing such positive outcomes, Sebela Pharmaceuticals is progressing toward submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The anticipated approval is set for January 2027, as they aim to make Tegoprazan a viable treatment option available on the market for managing GERD symptoms.

Conclusion

The insights presented from the TRIUMpH-NERD study at the ACG 2026 Meeting signal a promising advancement in treating gastroesophageal reflux disease. As many patients continue to experience debilitating symptoms, the ongoing commitment from Sebela Pharmaceuticals to innovate and deliver effective solutions remains crucial. The introduction of Tegoprazan promises to offer hope for improved management of conditions like NERD, marking an exciting development in gastrointestinal healthcare.